Mirtazapina Bluepharma (Mirtazapine)

Mirtazapine, the active ingredient in Mirtazapina Bluepharma, is a NaSSA (noradrenergic and specific serotonergic antidepressant) presented as an oral dosage form for oral use. It is indicated for the treatment of major depressive disorder in adult patients. It is marketed across the European Union and is prescribed by qualified healthcare professionals.

GNH USA supplies Mirtazapina Bluepharma as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide. The company adheres to stringent quality standards and provides reliable global distribution.

Mirtazapine is a NaSSA antidepressant used primarily in the management of depressive disorders.

- Major depressive disorder: reduces depressive symptoms and improves mood in adult patients.

Mirtazapine may cause a range of adverse reactions, which are generally classified by frequency and severity.

Common Side Effects: - Sedation: feeling of drowsiness or sleepiness - Increased appetite and weight gain - Dry mouth - Constipation

Serious or Rare Side Effects: - Severe neutropenia: marked reduction in white blood cells - Hypersensitivity reactions: rash, angioedema, anaphylaxis - Suicidal thoughts: emergence or worsening of suicidal ideation

When prescribing mirtazapine, clinicians should consider several safety measures. - Dose initiation: start with low dose and titrate under medical supervision - Monitoring: assess for worsening depression or emergence of suicidal thoughts - CNS depression: caution when combined with other sedatives - Metabolic effects: monitor weight and lipid profile - Pregnancy and lactation: use only if benefits outweigh risks - Store at ambient temperature: keep in original container, protect from moisture and light

Mirtazapine can interact with various medicines, requiring attention to the level of risk.

Major Interactions (Avoid): - Monoamine oxidase inhibitors (MAOIs): risk of hypertensive crisis - CYP2D6 inhibitors (e.g., fluoxetine, paroxetine): increased mirtazapine plasma levels - CNS depressants (e.g., benzodiazepines, alcohol): additive sedation

Moderate Interactions (Monitor Closely): - Other serotonergic agents (e.g., SSRIs, SNRIs): potential serotonin syndrome - Anticholinergic drugs: enhanced anticholinergic burden - Warfarin: possible alteration of anticoagulant effect